Emlorákos betegek kezelése fulvesztranttal -lehetne hatékonyabb?

Translated title of the contribution: Treating breast cancer patients with fulvestrant - Could it be more efficacious?

Research output: Contribution to journalArticle

1 Citation (Scopus)


Fulvestrant, as an estrogen-receptor antagonist, effectively decreases the estrogen effect, which is a key factor in the development, growth and progression of the breast cancer. Its clinical advantage can appear even after several lines of unsuccessful chemo- or hormonal therapy. In our invasive ductal carcinoma cases, the clinical benefit was obvious over 40%. According to recent data using a higher dose better results can be obtained. The same is expected if the drug would be applied at an earlier stage of the disease.

Original languageHungarian
Pages (from-to)733-736
Number of pages4
JournalLege Artis Medicinae
Issue number11
Publication statusPublished - Nov 1 2010


ASJC Scopus subject areas

  • Medicine(all)

Cite this